RT Journal Article SR Electronic T1 Tumor nekrozis faktor-alfa blockers and tuberculosis – Analysis of the 6 years JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP p1946 VO 38 IS Suppl 55 A1 Sermin Börekçi A1 Berna Duman A1 Nejdiye Mazican A1 Koray Tascilar A1 Benan Müsellim A1 Gül Öngen A1 Vedat Hamuryudan YR 2011 UL http://erj.ersjournals.com/content/38/Suppl_55/p1946.abstract AB Aim: It is a known fact that risk of tubercolosis infection is increased with tumor necrosis factor-alfa (TNF-α) blocker treatment. In this study we evaluated the last 6 years follow up data of the patients who admitted to our clinic for tuberculosis scanning before and during TNF-α blocker treatment.Method: Total of 2335 patients' follow up datas were evaluated between February 2005 and February 2011.Statistical analysis were done by using SPSS 15.0 statistical program.Results: There were 1186 (51%) male, 1149 (49%) female of total number of 2335 patients. Mean age was 40.32±14.67 years. Patients with the diagnosis of rheumatoid arthritis 785 (33.6%), ankylosing spondylitis 912 (39.1%), psoriatic arthritis 193 (8.3%), Behçet disease 85 (3.6%), Chron disease 65 (2.8%), juvenil rheumatoid artritis 142 (6.1%). 781 (33.9%) of the subjects had smoking history of an average 15.07±13.57 pack-year. 792 (33.9%) patients treated with Etanercept, 725 (31.0%) Infliximab, 567 (24.3%) Adalimumab. 66 (2.8%) patients had treatment for tuberculosis in the past, 112 (4.8%) patients had diabetes mellitus. Acording to RAED II (The Society for Research and Education in Rheumatology) Guideline; PPD was ≥5 mm in 1340 (57%), 101 (4.3%)had radiological fibrous lesion, 12 (0.5%) had contact history with tuberculosis. 1308 (56.0%) patients were given preventive treatment with Izoniazid. In these 6 years fallow up, 4 (171/100.000) patients had tuberculosis infection; 2 were miliary tuberculosis (one of them was multidrug resistant), 1 was gastrointestinal tuberculosis and the last one was relaps patient with a history of tuberculosis.Conclusion: This results supported that close follow up of patients who used TNF-α blocker was so important.